Search Results

Faron Pharmaceuticals Ltd. announces the nomination of its co-founders, Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, as finalists in the ‘SMEs’ category of the European Inventor Award 2024.

Faron Pharmaceuticals Ltd. announces that the extraordinary general meeting of the Company took place , September 22, 2023 in Turku, Finland.

Faron Pharmaceuticals Ltd. announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024.

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, announced audited full-year financial results for January 1 to December 31, 2023 and provided an overview of recent corporate developments.

Faron Pharmaceuticals Ltd. announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023.

Faron Pharmaceuticals Ltd. announces it will host a virtual BEXMAB update event on Tuesday, March 19 at 11.00 EET/9am GMT, following the most recent data cut-off and scheduled analysis.

Faron Pharmaceuticals Ltd will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.

Faron Pharmaceuticals Ltd. is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier.

Faron Pharmaceuticals Oy announces that Dr. Markku Jalkanen, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday January 11, 2024, at 12pm PT, in San Francisco.

Faron Pharmaceuticals Ltd. announced that the first patient has been dosed in Phase 2 of the BEXMAB trial that evaluates the safety and efficacy of bexmarilimab, in combination with standard of care in patients with hypomethylating agents -refractory or relapsed myelodysplastic syndrome, an aggressive myeloid leukemia with very few treatment options.